| Literature DB >> 25900267 |
Kazuhide Inage1, Yoshihiro Sakuma2, Kazuyo Yamauchi3, Akiko Suganami4, Sumihisa Orita5, Go Kubota6, Yasuhiro Oikawa7, Takeshi Sainoh8, Jun Sato9, Kazuki Fujimoto10, Yasuhiro Shiga11, Kazuhisa Takahashi12, Seiji Ohtori13, Yutaka Tamura14.
Abstract
BACKGROUND: Muscle injury is common and is thought to account for 10%-50% of all sports-related injuries. The use of rest, ice, compression, and elevation is common in clinical practice, but many treatments over a long period are required to produce a therapeutic effect. We evaluated the utility of photodynamic therapy as a new treatment option for the acute stage of muscle injury.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25900267 PMCID: PMC4406025 DOI: 10.1186/s13018-015-0193-9
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Figure 1Photodynamic therapy. (A) Injecting a light-sensitive substance (photosensitizer) into a biologic body. (B) Irradiating the target body tissue with light at a particular wavelength range and evolving active oxygen from the light-sensitive substances.
Figure 2Drop-mass method. (A) Schematic representation of the impact apparatus. (B) A 115-g weight was dropped from a height of 1 m through an acrylic guide tube. The weight was dropped onto an impacter, dividing the muscle belly without injuring the overlying skin.
Figure 3Schematic structure of the liposomally formulated indocyanine green derivative, designated as LP-iDOPE.
Figure 4Near-infrared laser irradiation system (light-emitting diode (LED) device, 810 nm; power, 0.1 W/cm2; irradiation time, 30 s). (A) LED device. (B) Covering the LED except the targeting spot. (C) Irradiation to the rat at 18 h after muscle injury.
Figure 5In vivo imaging system (In-Vivo FX PRO; BRUKER Corporation, Billerica, MA, USA).
Figure 6Average fluorescence values in the treatment and no treatment groups using the in vivo imaging system.
Figure 7Interleukin-6 levels in the muscle injury site at 18 h after muscle injury in the treatment and no treatment groups.
Figure 8Tumor necrosis factor-α levels in the muscle injury site at 18 h after muscle injury in the treatment and no treatment groups.
Figure 9Hematoxylin and eosin staining of local tissues. Transverse sections showing gastrocnemius muscular fibers. (A) No injury site (100×). (B) Treatment site at 24 h (100×). (C)No treatment site at 24 h (100×). (D) Treatment site at 24 h (400×). (E) No treatment site at 24 h (400×). (F) No injury site (100×). (G) Treatment site at 1 week (100×).